The Rodman & Renshaw Reiterates “Buy” Rating for Abeona Therapeutics Inc. (ABEO), Report finds

The Rodman & Renshaw Reiterates “Buy” Rating for Abeona Therapeutics Inc. (ABEO), Report finds

A number of other equities analysts have also recently issued reports on the stock. Maxim Group restated a “buy” rating and issued a $14.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, October 18th. Cantor Fitzgerald restated a “buy” rating and issued a $21.00 price objective on shares of Abeona Therapeutics in a research report on Friday, October 21st. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 18th. Jefferies Group LLC initiated coverage on shares of Abeona Therapeutics in a research report on Friday, January 6th. They issued a “buy” rating and a $11.00 price objective on the stock. Finally, FBR & Co restated an “outperform” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research report on Thursday, December 1st. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $15.18.

Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “buy” rating restated by research analysts at Rodman & Renshaw in a research note issued on Tuesday. They currently have a $20.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $17.00. Rodman & Renshaw’s price objective suggests a potential upside of 292.16% from the company’s current price.

Shares of Abeona Therapeutics (NASDAQ:ABEO) opened at 5.125 on Tuesday. Abeona Therapeutics has a 12-month low of $2.05 and a 12-month high of $9.44. The company has a 50 day moving average of $5.07 and a 200-day moving average of $5.38. The firm’s market cap is $204.79 million.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Thursday, November 10th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.11. Abeona Therapeutics had a negative net margin of 2,029.60% and a negative return on equity of 26.65%. Analysts predict that Abeona Therapeutics will post ($0.59) EPS for the current year.

A number of large investors have recently bought and sold shares of ABEO. Ardsley Advisory Partners acquired a new stake in Abeona Therapeutics during the third quarter valued at approximately $120,000. Highbridge Capital Management LLC acquired a new stake in Abeona Therapeutics during the third quarter valued at approximately $1,591,000. Baker BROS. Advisors LP acquired a new stake in Abeona Therapeutics during the third quarter valued at approximately $610,000. Knoll Capital Management LP acquired a new stake in Abeona Therapeutics during the third quarter valued at approximately $8,036,000. Finally, RTW Investments LLC acquired a new stake in Abeona Therapeutics during the third quarter valued at approximately $116,000. 17.43% of the stock is currently owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.

Related posts

Leave a Comment